June 2026 Thermo Fisher Scientific expanded its in vitro toxicology portfolio by introducing advanced cell-based assay solutions and high-content screening technologies. The product launch strengthened predictive toxicology workflows for pharmaceutical, biotechnology, and chemical safety testing.
May 2026 Charles River Laboratories expanded its non-clinical safety assessment services through investments in advanced in vitro toxicology platforms and laboratory automation. The expansion enhanced capabilities for early-stage drug safety evaluation and regulatory toxicology studies.
April 2026 Eurofins Scientific expanded its global toxicology testing network by introducing new in vitro testing services for pharmaceuticals, medical devices, and industrial chemicals. The initiative supported regulatory compliance while reducing reliance on animal testing.
March 2026 Labcorp expanded its drug development portfolio with enhanced in vitro toxicology services integrating organ-on-chip models, advanced cell culture systems, and AI-driven data analysis to improve predictive safety assessments.